DMAAU

Drugs Made In America Acquisition Corp. Units
DMAAU

1 day

0.00%

5 days

0.00%

1 month

0.00%

3 months

0.00%

6 months

0.00%

Year to date

0.00%

1 year

0.00%

5 years

0.00%

10 years

0.00%

About: Drugs Made In America Acquisition Corp is a blank check company.

Financials Shell Companies

0

Funds holding %

of 7,202 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14.28% more ownership

Funds ownership: 0% [Q4 2024] → 14.28% (+14.28%) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for DMAAU.

See Analyst Rankings

Financial journalist opinion

Drugs Made in America Acquisition Corp. Announces Advisory Team

Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactively pursue the deliverable of a business or combinations that seeks to become a new competitive cost producer of drugs made in America. Onboarding production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America.

Drugs Made in America Acquisition Corp. Announces Advisory Team

See News Rankings

Charts implemented using Lightweight Charts™